Advanced in Siderosis

Hans R. Jager

UCL Queen Square Institute Of Neurology
London, ENG, GB 
Advanced in Siderosis
UCL Queen Square Institute Of Neurology
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Hans Jager practices in London, United Kingdom. Mr. Jager is rated as an Advanced expert by MediFind in the treatment of Siderosis. His top areas of expertise are HIV/AIDS, Cerebral Amyloid Angiopathy, Transient Ischemic Attack (TIA), Gamma Knife Radiosurgery, and Stent Placement.

His clinical research consists of co-authoring 191 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Siderosis.

Gender
Male

Locations

UCL Queen Square Institute of Neurology
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
Enrollment Status: Completed
Publish Date: August 17, 2025
Intervention Type: Other
Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2-Drug Regimen Juluca, a Onepill-Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2-Drug Regimen Juluca, a Onepill-Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
View 2 Less Clinical Trials

191 Total Publications

Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis.
Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis.
Journal: Neurology
Published: August 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jager's expertise for a condition
ConditionClose
    View All 38 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile